Qiagen Unveils New Lentivirus Kits for Cell and Gene Therapy

These solutions aim to support the production of advanced biotherapeutics, such as CAR-T, a personalized cancer immunotherapy.

Qiagen has expanded its digital PCR (dPCR) portfolio with improved solutions for lentivirus-based applications. 

These solutions aim to support the production of advanced biotherapeutics, such as CAR-T, a personalized cancer immunotherapy.

This development strengthens Qiagen’s commitment to providing high-precision quality control (QC) solutions in manufacturing cell and gene therapy (CGT).

The new offering is designed to support biotech companies, Contract Development and Manufacturing Organisations (CDMOs), and therapy developers by providing standardised and reliable QC workflows critical for safe and effective biotherapeutic production.

Enhanced accuracy and safety with new kits

Qiagen’s newly introduced QIAcuity RCL Quant Kit targets replication-competent lentivirus (RCL), a key safety concern in lentiviral vector production. This kit is equipped with step-by-step protocols that detect even small amounts of RCL, ensuring compliance with safety regulations and helping developers maintain the integrity of their treatments.

Additionally, Qiagen has launched a series of new QIAcuity CGT dPCR assays, which include eight wet-lab verified lentiviral targets. These assays are designed for viral vector genome titration, which measures the number of therapeutic virus particles, and vector copy number (VCN) determination, which counts the number of gene copies inserted into each cell.

Streamlined process with new Lysis Kit

The launch also includes the QIAcuity CGT Lentivirus Lysis Kit, which, combined with the dPCR assays, allows for accurate vector genome titer quantification with fewer hands-on steps. 

Additionally, this solution is designed to enhance the overall accuracy and repeatability of testing, improving efficiency in CGT manufacturing.